Want to see ANIP full AI Analyst Report?
ANIP Stock Chart & Stats
$80.92
<$0.01(0.02%)
At close: 4:00 PM EST
$80.92
<$0.01(0.02%)
Day’s Range― - ―
52-Week Range$62.61 - $99.50
Previous CloseN/A
Volume18.69K
Average Volume (3M)376.99K
Market Cap
$1.89B
Enterprise Value$1.85B
Total Cash (Recent Filing)$311.18M
Total Debt (Recent Filing)$327.76M
Price to Earnings (P/E)20.2
Beta0.50
Next Earnings
Aug 12, 2026EPS Estimate
2.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.11
Shares Outstanding22,734,617
10 Day Avg. Volume273,316
30 Day Avg. Volume376,989
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)2.93
Price to Sales (P/S)1.79
P/FCF Ratio10.49
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit3.03
Enterprise Value/Ebitda7.87
Forecast
1Y Price Target
$114.00Price Target Upside40.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)9.34
Revenue Forecast (FY)$1.12B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Scale-upMulti-year revenue growth shows durable commercial traction across branded and generic lines. Scale reduces per-unit costs, funds reinvestment in launches and rare-disease commercialization, and increases resilience versus single-product volatility over the next 2–6 months.
Strong Free Cash Flow GenerationConsistent FCF provides durable flexibility for buybacks, M&A and commercial expansion. High absolute cash flow supports deleveraging and investment in sales force and launches, enabling sustainable growth funding without reliance on dilutive financing in the medium term.
Rare-disease Leadership And Product CadenceStrong Cortrophin growth plus steady generics launch cadence and in-house manufacturing give structural competitive advantage: vertical control of supply and commercialization accelerates time-to-market, supports margins, and underpins predictable product flow over coming quarters.
Bears Say
Gross Margin CompressionA durable shift toward royalty-bearing and partnered product mix can suppress gross margins versus historical peaks. If higher-margin legacy sales do not return, persistent margin compression will limit operating leverage from revenue growth and pressure long-term profitability.
Revenue Concentration In Cortrophin/Rare DiseaseHeavy reliance on one product class raises structural concentration risk: reimbursement, access issues, or demand shifts for Cortrophin or Rare Disease channels could materially affect consolidated results and amplify volatility over the medium term.
Balance-sheet And Cash-conversion VolatilityPrior leverage spikes and inconsistent OCF-to-EBITDA conversion indicate sensitivity to working capital and timing items. Such volatility can constrain flexibility for M&A or sustained buybacks during downturns and increases refinancing and execution risk over the next several quarters.
ANI Pharmaceuticals News
ANIP FAQ
What was Ani Pharmaceuticals’s price range in the past 12 months?
Ani Pharmaceuticals lowest stock price was $62.60 and its highest was $99.50 in the past 12 months.
What is Ani Pharmaceuticals’s market cap?
Ani Pharmaceuticals’s market cap is $1.89B.
When is Ani Pharmaceuticals’s upcoming earnings report date?
Ani Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 41 days.
How were Ani Pharmaceuticals’s earnings last quarter?
Ani Pharmaceuticals released its earnings results on May 08, 2026. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.299 by $0.751.
Is Ani Pharmaceuticals overvalued?
According to Wall Street analysts Ani Pharmaceuticals’s price is currently Undervalued.
Does Ani Pharmaceuticals pay dividends?
Ani Pharmaceuticals does not currently pay dividends.
What is Ani Pharmaceuticals’s EPS estimate?
Ani Pharmaceuticals’s EPS estimate is 2.01.
How many shares outstanding does Ani Pharmaceuticals have?
Ani Pharmaceuticals has 22,734,617 shares outstanding.
What happened to Ani Pharmaceuticals’s price movement after its last earnings report?
Ani Pharmaceuticals reported an EPS of $2.05 in its last earnings report, beating expectations of $1.299. Following the earnings report the stock price went down -2.443%.
Which hedge fund is a major shareholder of Ani Pharmaceuticals?
Currently, no hedge funds are holding shares in ANIP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ANI Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$114.00 (40.88% Upside)
$114.00 (40.88% Upside)
Blogger Sentiment
Bullish
ANIP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 769.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.86%
12-Months-Change
Fundamentals
Return on Equity
17.32%
Trailing 12-Months
Asset Growth
10.02%
Trailing 12-Months
Company Description
Ani Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANIP Company Deck
ANIP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and material financial progress: consolidated Q1 revenue growth (20% YoY), Cortrophin Gel growth (42% YoY), adjusted EBITDA and EPS expansion, raised 2026 guidance, near-term cash from an IP out-license, an active product launch cadence in Generics, and a sizeable commercial expansion into acute gouty arthritis flares. Offsetting items include margin pressure from a higher mix of royalty-bearing products and new launches, temporary insurance reverification and access headwinds that impacted Q1 timing, increased SG&A from sales expansion, and some reliance on timing of upfront/milestone payments. Overall, positives (revenue/EBITDA growth, guidance raise, strategic investments and M&A optionality, cash position, repurchase program) materially outweigh the lowlights (margin compression, access and timing issues), supporting a constructive outlook for 2026 and into 2027.View all ANIP earnings summariesANIP Stock 12 Month Forecast
Average Price Target
$114.00
▲(40.88% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Harrow Health
―
Ownership Overview
7.96% Insiders
19.67% Mutual Funds
38.53% Other Institutional Investors
9.97% Public Companies and
Individual Investors